These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 22771474

  • 1. Methamphetamine binds to α-synuclein and causes a conformational change which can be detected by nanopore analysis.
    Tavassoly O, Lee JS.
    FEBS Lett; 2012 Sep 21; 586(19):3222-8. PubMed ID: 22771474
    [Abstract] [Full Text] [Related]

  • 2. The use of nanopore analysis for discovering drugs which bind to α-synuclein for treatment of Parkinson's disease.
    Tavassoly O, Kakish J, Nokhrin S, Dmitriev O, Lee JS.
    Eur J Med Chem; 2014 Dec 17; 88():42-54. PubMed ID: 25081642
    [Abstract] [Full Text] [Related]

  • 3. Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation.
    Liu IH, Uversky VN, Munishkina LA, Fink AL, Halfter W, Cole GJ.
    Glycobiology; 2005 Dec 17; 15(12):1320-31. PubMed ID: 16037493
    [Abstract] [Full Text] [Related]

  • 4. Α-synuclein misfolding and Parkinson's disease.
    Breydo L, Wu JW, Uversky VN.
    Biochim Biophys Acta; 2012 Feb 17; 1822(2):261-85. PubMed ID: 22024360
    [Abstract] [Full Text] [Related]

  • 5. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
    Chaari A, Hoarau-Véchot J, Ladjimi M.
    Int J Biol Macromol; 2013 Sep 17; 60():196-205. PubMed ID: 23748003
    [Abstract] [Full Text] [Related]

  • 6. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM, Ophof A, Broe M, Jensen PH, Kettle E, Fedorow H, Cartwright MI, Griffiths FM, Shepherd CE, Double KL.
    Brain; 2005 Nov 17; 128(Pt 11):2654-64. PubMed ID: 16000336
    [Abstract] [Full Text] [Related]

  • 7. Anti-aggregation and fibril-destabilizing effects of sex hormones on alpha-synuclein fibrils in vitro.
    Hirohata M, Ono K, Morinaga A, Ikeda T, Yamada M.
    Exp Neurol; 2009 Jun 17; 217(2):434-9. PubMed ID: 19289119
    [Abstract] [Full Text] [Related]

  • 8. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation.
    Uversky VN.
    J Neurochem; 2007 Oct 17; 103(1):17-37. PubMed ID: 17623039
    [Abstract] [Full Text] [Related]

  • 9. Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro.
    Welander H, Bontha SV, Näsström T, Karlsson M, Nikolajeff F, Danzer K, Kostka M, Kalimo H, Lannfelt L, Ingelsson M, Bergström J.
    Biochem Biophys Res Commun; 2011 Aug 19; 412(1):32-8. PubMed ID: 21798243
    [Abstract] [Full Text] [Related]

  • 10. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies.
    Fodero-Tavoletti MT, Mulligan RS, Okamura N, Furumoto S, Rowe CC, Kudo Y, Masters CL, Cappai R, Yanai K, Villemagne VL.
    Eur J Pharmacol; 2009 Sep 01; 617(1-3):54-8. PubMed ID: 19576880
    [Abstract] [Full Text] [Related]

  • 11. Isomers of human alpha-synuclein stabilized by disulfide bonds exhibit distinct structural and aggregative properties.
    Jiang C, Chang JY.
    Biochemistry; 2007 Jan 16; 46(2):602-9. PubMed ID: 17209570
    [Abstract] [Full Text] [Related]

  • 12. Parkinson's disease with dementia, lewy-body disorders and alpha-synuclein: recent advances and a case report.
    Wu CK.
    Acta Neurol Taiwan; 2011 Mar 16; 20(1):4-14. PubMed ID: 21560084
    [Abstract] [Full Text] [Related]

  • 13. Dynamic modeling of α-synuclein aggregation in dopaminergic neuronal system indicates points of neuroprotective intervention: experimental validation with implications for Parkinson's therapy.
    Sultana Z, Paleologou KE, Al-Mansoori KM, Ardah MT, Singh N, Usmani S, Jiao H, Martin FL, Bharath MM, Vali S, El-Agnaf OM.
    Neuroscience; 2011 Dec 29; 199():303-17. PubMed ID: 22056602
    [Abstract] [Full Text] [Related]

  • 14. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM, Trojanowski JQ.
    Neuron; 2006 Oct 05; 52(1):33-8. PubMed ID: 17015225
    [Abstract] [Full Text] [Related]

  • 15. Cu(II) and dopamine bind to α-synuclein and cause large conformational changes.
    Tavassoly O, Nokhrin S, Dmitriev OY, Lee JS.
    FEBS J; 2014 Jun 05; 281(12):2738-53. PubMed ID: 24725464
    [Abstract] [Full Text] [Related]

  • 16. Interaction with synphilin-1 promotes inclusion formation of alpha-synuclein: mechanistic insights and pathological implication.
    Xie YY, Zhou CJ, Zhou ZR, Hong J, Che MX, Fu QS, Song AX, Lin DH, Hu HY.
    FASEB J; 2010 Jan 05; 24(1):196-205. PubMed ID: 19762560
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M, Iwatsubo T, Mizuno Y, Mochizuki H.
    J Neurochem; 2004 Oct 05; 91(2):451-61. PubMed ID: 15447678
    [Abstract] [Full Text] [Related]

  • 19. Dopamine facilitates alpha-synuclein oligomerization in human neuroblastoma SH-SY5Y cells.
    Yamakawa K, Izumi Y, Takeuchi H, Yamamoto N, Kume T, Akaike A, Takahashi R, Shimohama S, Sawada H.
    Biochem Biophys Res Commun; 2010 Jan 01; 391(1):129-34. PubMed ID: 19900407
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.